| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Clopidogrel bisulfate (USP); Clopidogrel sulfate (JP18); Clopidogrel sulfate tablets (JP18); Clopidogrel hydrogen sulphate; Isocover (TN); Plavix (TN) | ||||||||||
| Product | PLAVIX (sanofi-aventis U.S. LLC) | ||||||||||
| Generic | CLOPIDOGREL (A-S Medication Solutions), CLOPIDOGREL (A-S Medication Solutions), CLOPIDOGREL (Accord Healthcare), CLOPIDOGREL (Amneal Pharmaceuticals LLC), CLOPIDOGREL (Bryant Ranch Prepack), CLOPIDOGREL (Bryant Ranch Prepack), CLOPIDOGREL (Bryant Ranch Prepack), CLOPIDOGREL (Cadila Healthcare Limited), CLOPIDOGREL (DIRECT RX), CLOPIDOGREL (Denton Pharma), CLOPIDOGREL (Direct_Rx), CLOPIDOGREL (Macleods Pharmaceuticals Limited), CLOPIDOGREL (NorthStar RxLLC), CLOPIDOGREL (NuCare Pharmaceuticals), CLOPIDOGREL (NuCare Pharmaceuticals), CLOPIDOGREL (NuCare Pharmaceuticals), CLOPIDOGREL (POLYGEN PHARMACEUTICALS), CLOPIDOGREL (Preferred Pharmaceuticals), CLOPIDOGREL (Preferred Pharmaceuticals), CLOPIDOGREL (Proficient Rx LP), CLOPIDOGREL (REMEDYREPACK), CLOPIDOGREL (Teva Pharmaceuticals USA), CLOPIDOGREL (Vensun Pharmaceuticals), CLOPIDOGREL (Viona Pharmaceuticals), CLOPIDOGREL (A-S Medication Solutions), CLOPIDOGREL (A-S Medication Solutions), CLOPIDOGREL BISULFATE (A-S Medication Solutions), CLOPIDOGREL (A-S Medication Solutions), CLOPIDOGREL BISULFATE (ACI Healthcare USA), CLOPIDOGREL (American Health Packaging), CLOPIDOGREL (Aphena Pharma Solutions - Tennessee), CLOPIDOGREL (Apotex Corp.), CLOPIDOGREL (Aurobindo Pharma Limited), CLOPIDOGREL (AvPAK), CLOPIDOGREL BISULFATE (Bryant Ranch Prepack), CLOPIDOGREL BISULFATE (Bryant Ranch Prepack), CLOPIDOGREL BISULFATE (Bryant Ranch Prepack), CLOPIDOGREL (Bryant Ranch Prepack), CLOPIDOGREL BISULFATE (Bryant Ranch Prepack), CLOPIDOGREL BISULFATE (Cardinal Health), CLOPIDOGREL (Clinical Solutions Wholesale), CLOPIDOGREL BISULFATE (Denton Pharma), CLOPIDOGREL BISULFATE (Dr.Reddy's Laboratories Limited), CLOPIDOGREL BISULFATE (Dr.Reddy's Laboratories Limited), CLOPIDOGREL BISULFATE (Golden State Medical Supply), CLOPIDOGREL (Golden State Medical Supply), CLOPIDOGREL (Legacy Pharmaceutical Packaging), CLOPIDOGREL (Major Pharmaceuticals), CLOPIDOGREL BISULFATE (Major Pharmaceuticals), CLOPIDOGREL BISULFATE (McKesson Corporation dba SKY Packaging), CLOPIDOGREL (NCS HealthCare of KY), CLOPIDOGREL BISULFATE (NuCare Pharmaceuticals), CLOPIDOGREL BISULFATE (NuCare Pharmaceuticals), CLOPIDOGREL BISULFATE (PD-Rx Pharmaceuticals), CLOPIDOGREL BISULFATE (Preferred Pharmaceuticals), CLOPIDOGREL BISULFATE (Proficient Rx LP), CLOPIDOGREL (Proficient Rx LP), CLOPIDOGREL (RPK Pharmaceuticals), CLOPIDOGREL (Rising Pharmaceuticals), CLOPIDOGREL BISULFATE (ScieGen Pharmaceuticals), CLOPIDOGREL BISULFATE (Sun Pharmaceutical Industries), CLOPIDOGREL BISULFATE (Torrent Pharmaceuticals Limited), CLOPIDOGREL (Westminster Pharmaceuticals), CLOPIDOGREL (A-S Medication Solutions), CLOPIDOGREL (NuCare Pharmaceuticals), CLOPIDOGREL (REMEDYREPACK) | ||||||||||
| Formula | C16H16ClNO2S. H2SO4 | ||||||||||
| Exact mass | 419.0264 | ||||||||||
| Mol weight | 419.9002 | ||||||||||
| Structure |  | ||||||||||
| Simcomp | |||||||||||
| Class | Blood modifier agent DG01950 Antithrombotic agent DG01712 Antiplatelet agent DG01808 Thienopyridine DG01809 P2Y12 receptor antagonist DG01808 Thienopyridine Metabolizing enzyme substrate DG01892 CYP1A2 substrate DG02919 CYP2B6 substrate DG01639 CYP2C19 substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate Metabolizing enzyme inhibitor DG01641 CYP2C8 inhibitor | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Anticoagulant, Platelet aggregation inhibitor, Purinergic receptor P2Y12 antagonist | ||||||||||
| Disease | Myocardial infarction [DS:H01730] | ||||||||||
| Comment | Thienopyridine derivative CYP2C19 poor metabolizer status is associated with diminished response to Clopidogrel. | ||||||||||
| Target | P2RY12 [HSA:64805] [KO:K04298] | ||||||||||
| Metabolism | Enzyme: CYP2C19 [HSA:1557]; CYP3A4 [HSA:1576], CYP1A2 [HSA:1544], CYP2B6 [HSA:1555] | ||||||||||
| Interaction | CYP inhibition: CYP2C8 [HSA:1558] | ||||||||||
| Structure map |
| ||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] B BLOOD AND BLOOD FORMING ORGANS B01 ANTITHROMBOTIC AGENTS B01A ANTITHROMBOTIC AGENTS B01AC Platelet aggregation inhibitors excl. heparin B01AC04 Clopidogrel D00769 Clopidogrel bisulfate (USP) <JP/US> USP drug classification [BR:br08302] Blood Products and Modifiers Platelet Modifying Agents Adenosine Diphosphate P2Y12 Clopidogrel D00769 Clopidogrel bisulfate (USP) Therapeutic category of drugs in Japan [BR:br08301] 3 Agents affecting metabolism 33 Blood and body fluid agents 339 Miscellaneous 3399 Others D00769 Clopidogrel bisulfate (USP); Clopidogrel sulfate (JP18); Clopidogrel sulfate tablets (JP18) Drug groups [BR:br08330] Blood modifier agent DG01950 Antithrombotic agent DG01712 Antiplatelet agent DG01808 Thienopyridine DG00155 Clopidogrel D00769 Clopidogrel bisulfate DG01809 P2Y12 receptor antagonist DG01808 Thienopyridine DG00155 Clopidogrel D00769 Clopidogrel bisulfate Metabolizing enzyme substrate DG01892 CYP1A2 substrate DG00155 Clopidogrel D00769 Clopidogrel bisulfate DG02919 CYP2B6 substrate DG00155 Clopidogrel D00769 Clopidogrel bisulfate DG01639 CYP2C19 substrate DG00155 Clopidogrel D00769 Clopidogrel bisulfate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG00155 Clopidogrel D00769 Clopidogrel bisulfate Metabolizing enzyme inhibitor DG01641 CYP2C8 inhibitor DG00155 Clopidogrel D00769 Clopidogrel bisulfate Target-based classification of drugs [BR:br08310] G Protein-coupled receptors Rhodopsin family Purine / pyrimidine P2RY12 D00769 Clopidogrel bisulfate (USP) <JP/US> Drugs listed in the Japanese Pharmacopoeia [BR:br08311] Chemicals D00769 Clopidogrel sulfate D00769 Clopidogrel sulfate tablets New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D00769 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D00769 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D00769 Pharmacogenomic biomarkers [br08341.html] Polymorphisms and mutations affecting drug response D00769 Drug groups [BR:br08330] Blood modifier agent DG01950 Antithrombotic agent DG01712 Antiplatelet agent DG01808 Thienopyridine DG00155 Clopidogrel DG01809 P2Y12 receptor antagonist DG01808 Thienopyridine DG00155 Clopidogrel Metabolizing enzyme substrate DG01892 CYP1A2 substrate DG00155 Clopidogrel DG02919 CYP2B6 substrate DG00155 Clopidogrel DG01639 CYP2C19 substrate DG00155 Clopidogrel DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG00155 Clopidogrel Metabolizing enzyme inhibitor DG01641 CYP2C8 inhibitor DG00155 Clopidogrel | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 26 1 N1y N 21.9223 -14.0768 2 C1c C 20.7116 -14.7786 3 C1x C 23.1271 -14.7786 4 C1x C 21.9164 -12.6791 5 C8y C 19.5011 -14.0768 6 C7a C 20.7116 -16.1766 7 C8y C 24.3378 -14.0827 8 C1x C 23.1271 -11.9773 9 C8y C 19.5011 -12.6791 10 C8x C 18.2904 -14.7786 11 O7a O 19.5011 -16.8782 12 O6a O 21.9223 -16.8725 13 C8y C 24.3378 -12.6791 14 C8x C 25.6771 -14.5154 15 C8x C 18.2904 -11.9773 16 X Cl 20.7116 -11.9773 17 C8x C 17.0797 -14.0768 18 C1a C 18.2904 -16.1766 19 S2x S 25.6712 -12.2405 20 C8x C 26.5018 -13.3751 21 C8x C 17.0797 -12.6791 22 S4a S 29.6520 -14.3900 23 O1d O 29.6520 -12.9900 24 O1d O 29.6520 -15.7900 25 O1d O 28.2519 -14.3900 26 O1d O 31.0519 -14.3900 BOND 27 1 2 5 1 2 2 6 1 #Down 3 3 7 1 4 4 8 1 5 5 9 1 6 5 10 2 7 6 11 1 8 6 12 2 9 7 13 2 10 7 14 1 11 9 15 2 12 9 16 1 13 10 17 1 14 11 18 1 15 13 19 1 16 14 20 2 17 15 21 1 18 8 13 1 19 17 21 2 20 19 20 1 21 1 2 1 22 1 3 1 23 1 4 1 24 22 23 2 25 22 24 2 26 22 25 1 27 22 26 1 |